Cargando…

The Potential Mechanism Behind Native and Therapeutic Collaterals in Moyamoya

BACKGROUND AND PURPOSE: To explore the genetic basis and molecular mechanism of native arteriogenesis and therapeutic synangiosis in moyamoya disease (MMD). METHODS: An angiography-based study using patients from a prospective trial of encephaloduroarteriosynangiosis (EDAS) surgery was performed. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Bao, Xiang-Yang, Fan, Yan-Na, Wang, Qian-Nan, Wang, Xiao-Peng, Yang, Ri-Miao, Zou, Zheng-Xing, Zhang, Qian, Li, De-Sheng, Duan, Lian, Yu, Xin-Guang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086844/
https://www.ncbi.nlm.nih.gov/pubmed/35557620
http://dx.doi.org/10.3389/fneur.2022.861184
_version_ 1784704093355245568
author Bao, Xiang-Yang
Fan, Yan-Na
Wang, Qian-Nan
Wang, Xiao-Peng
Yang, Ri-Miao
Zou, Zheng-Xing
Zhang, Qian
Li, De-Sheng
Duan, Lian
Yu, Xin-Guang
author_facet Bao, Xiang-Yang
Fan, Yan-Na
Wang, Qian-Nan
Wang, Xiao-Peng
Yang, Ri-Miao
Zou, Zheng-Xing
Zhang, Qian
Li, De-Sheng
Duan, Lian
Yu, Xin-Guang
author_sort Bao, Xiang-Yang
collection PubMed
description BACKGROUND AND PURPOSE: To explore the genetic basis and molecular mechanism of native arteriogenesis and therapeutic synangiosis in moyamoya disease (MMD). METHODS: An angiography-based study using patients from a prospective trial of encephaloduroarteriosynangiosis (EDAS) surgery was performed. The spontaneous collaterals grades were evaluated according to the system described by a new grading system. Blood samples were collected from all the recruited patients before EDAS and during the second hospitalization 3 months post-EDAS. We performed Boolean analysis using a combination of specific cell surface markers of CD34(bri)CD133(+)CD45(dim)KDR(+). Genotyping of p.R4810K was also performed. The correlation of age, sex, initial symptoms at diagnosis, collateral grade, Suzuki stages, the RNF213 genotype, time to peak (TTP), and endothelial progenitor cell (EPC) count with good collateral circulation was evaluated. RESULTS: Eighty-five patients with MMD were included in this study. The mutation rate of RNF213 p.R4810K in our study was 25.9% (22/85). The heterozygous mutations were occurred significantly more frequently in the cases that were presented with infarction, worse neurological status, severe posterior cerebral artery (PCA) stenosis, and longer TTP delay. Further, the heterozygous mutations occurred significantly more frequently in the poor collateral stage group. Lower grades were significantly correlated with severe ischemia symptoms, worse neurological status, and a longer TTP delay. The post-operative angiographic findings showed that a good Matsushima grade was correlated with heterozygous mutations, a lower collateral stage, and a longer TTP delay. The CD34(bri)CD133(+)CD45(dim)KDR(+) cell count in patients 3 months post-EDAS was significantly higher as compared to the count before EDAS in the good Matsushima grade group. However, this change was not observed in the poor Matsushima grade group. CONCLUSIONS: These data imply that mutations of RNF213 p.R4810K affect the establishment of spontaneous collateral circulation, and EPCs are involved in the process of formation of new EDAS collaterals.
format Online
Article
Text
id pubmed-9086844
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90868442022-05-11 The Potential Mechanism Behind Native and Therapeutic Collaterals in Moyamoya Bao, Xiang-Yang Fan, Yan-Na Wang, Qian-Nan Wang, Xiao-Peng Yang, Ri-Miao Zou, Zheng-Xing Zhang, Qian Li, De-Sheng Duan, Lian Yu, Xin-Guang Front Neurol Neurology BACKGROUND AND PURPOSE: To explore the genetic basis and molecular mechanism of native arteriogenesis and therapeutic synangiosis in moyamoya disease (MMD). METHODS: An angiography-based study using patients from a prospective trial of encephaloduroarteriosynangiosis (EDAS) surgery was performed. The spontaneous collaterals grades were evaluated according to the system described by a new grading system. Blood samples were collected from all the recruited patients before EDAS and during the second hospitalization 3 months post-EDAS. We performed Boolean analysis using a combination of specific cell surface markers of CD34(bri)CD133(+)CD45(dim)KDR(+). Genotyping of p.R4810K was also performed. The correlation of age, sex, initial symptoms at diagnosis, collateral grade, Suzuki stages, the RNF213 genotype, time to peak (TTP), and endothelial progenitor cell (EPC) count with good collateral circulation was evaluated. RESULTS: Eighty-five patients with MMD were included in this study. The mutation rate of RNF213 p.R4810K in our study was 25.9% (22/85). The heterozygous mutations were occurred significantly more frequently in the cases that were presented with infarction, worse neurological status, severe posterior cerebral artery (PCA) stenosis, and longer TTP delay. Further, the heterozygous mutations occurred significantly more frequently in the poor collateral stage group. Lower grades were significantly correlated with severe ischemia symptoms, worse neurological status, and a longer TTP delay. The post-operative angiographic findings showed that a good Matsushima grade was correlated with heterozygous mutations, a lower collateral stage, and a longer TTP delay. The CD34(bri)CD133(+)CD45(dim)KDR(+) cell count in patients 3 months post-EDAS was significantly higher as compared to the count before EDAS in the good Matsushima grade group. However, this change was not observed in the poor Matsushima grade group. CONCLUSIONS: These data imply that mutations of RNF213 p.R4810K affect the establishment of spontaneous collateral circulation, and EPCs are involved in the process of formation of new EDAS collaterals. Frontiers Media S.A. 2022-04-26 /pmc/articles/PMC9086844/ /pubmed/35557620 http://dx.doi.org/10.3389/fneur.2022.861184 Text en Copyright © 2022 Bao, Fan, Wang, Wang, Yang, Zou, Zhang, Li, Duan and Yu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Bao, Xiang-Yang
Fan, Yan-Na
Wang, Qian-Nan
Wang, Xiao-Peng
Yang, Ri-Miao
Zou, Zheng-Xing
Zhang, Qian
Li, De-Sheng
Duan, Lian
Yu, Xin-Guang
The Potential Mechanism Behind Native and Therapeutic Collaterals in Moyamoya
title The Potential Mechanism Behind Native and Therapeutic Collaterals in Moyamoya
title_full The Potential Mechanism Behind Native and Therapeutic Collaterals in Moyamoya
title_fullStr The Potential Mechanism Behind Native and Therapeutic Collaterals in Moyamoya
title_full_unstemmed The Potential Mechanism Behind Native and Therapeutic Collaterals in Moyamoya
title_short The Potential Mechanism Behind Native and Therapeutic Collaterals in Moyamoya
title_sort potential mechanism behind native and therapeutic collaterals in moyamoya
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086844/
https://www.ncbi.nlm.nih.gov/pubmed/35557620
http://dx.doi.org/10.3389/fneur.2022.861184
work_keys_str_mv AT baoxiangyang thepotentialmechanismbehindnativeandtherapeuticcollateralsinmoyamoya
AT fanyanna thepotentialmechanismbehindnativeandtherapeuticcollateralsinmoyamoya
AT wangqiannan thepotentialmechanismbehindnativeandtherapeuticcollateralsinmoyamoya
AT wangxiaopeng thepotentialmechanismbehindnativeandtherapeuticcollateralsinmoyamoya
AT yangrimiao thepotentialmechanismbehindnativeandtherapeuticcollateralsinmoyamoya
AT zouzhengxing thepotentialmechanismbehindnativeandtherapeuticcollateralsinmoyamoya
AT zhangqian thepotentialmechanismbehindnativeandtherapeuticcollateralsinmoyamoya
AT lidesheng thepotentialmechanismbehindnativeandtherapeuticcollateralsinmoyamoya
AT duanlian thepotentialmechanismbehindnativeandtherapeuticcollateralsinmoyamoya
AT yuxinguang thepotentialmechanismbehindnativeandtherapeuticcollateralsinmoyamoya
AT baoxiangyang potentialmechanismbehindnativeandtherapeuticcollateralsinmoyamoya
AT fanyanna potentialmechanismbehindnativeandtherapeuticcollateralsinmoyamoya
AT wangqiannan potentialmechanismbehindnativeandtherapeuticcollateralsinmoyamoya
AT wangxiaopeng potentialmechanismbehindnativeandtherapeuticcollateralsinmoyamoya
AT yangrimiao potentialmechanismbehindnativeandtherapeuticcollateralsinmoyamoya
AT zouzhengxing potentialmechanismbehindnativeandtherapeuticcollateralsinmoyamoya
AT zhangqian potentialmechanismbehindnativeandtherapeuticcollateralsinmoyamoya
AT lidesheng potentialmechanismbehindnativeandtherapeuticcollateralsinmoyamoya
AT duanlian potentialmechanismbehindnativeandtherapeuticcollateralsinmoyamoya
AT yuxinguang potentialmechanismbehindnativeandtherapeuticcollateralsinmoyamoya